Optimind Pharma

Optimind Pharma Gross Margin

Gross Margin of Optimind Pharma (OMND.CN) as of Oct 17, 2026.

Gross Margin

-

Last updated:

Gross Margin of Optimind Pharma is 2026 - . Gross Margin of Optimind Pharma was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optimind Pharma Stock analysis

What does Optimind Pharma do? Optimind Pharma Corp, headquartered in London, Ontario, provides medical cannabis and ketamine-assisted treatment for mental health conditions such as PTSD, anxiety, and depression. The company offers two treatment types—monotherapy and assisted therapy—using ketamine capsules, with effects felt within 30 minutes and cognitive restoration within two hours. It partners with psilocybin treatment developers to expand its therapeutic programs, which integrate psychedelic medicine with therapeutic processing based on scientific research. Optimind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optimind Pharma stock

On Eulerpool you can find the complete historical development of Gross Margin Optimind Pharma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Optimind Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Optimind Pharma

All Key Metrics — Optimind Pharma